MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: MTB-Beschluss Kim Musterperson

Raw json | Download

{
  "resourceType" : "CarePlan",
  "id" : "mii-exa-mtb-kim-musterperson-therapieplan",
  "meta" : {
    "profile" : [
      🔗 "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieplan|2027.0.0-ballot.1"
    ]
  },
  "language" : "de",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: CarePlan mii-exa-mtb-kim-musterperson-therapieplan</b></p><a name=\"de-mii-exa-mtb-kim-musterperson-therapieplan\"> </a><a name=\"de-hcmii-exa-mtb-kim-musterperson-therapieplan\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-mii-pr-mtb-therapieplan.html\">MII PR MTB Therapieplan</a> version: 2027.0.0-ballot.1</p></div><p><b>status</b>: Active</p><p><b>intent</b>: Plan</p><p><b>category</b>: <span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ praeth}\">prätherapeutische Tumorkonferenz (Festlegung der Therapiestrategie)</span></p><p><b>subject</b>: <a href=\"Patient-PatientKimMusterperson.html\">Kim Musterperson  (no stated gender), DoB: 1956-03-14</a></p><p><b>created</b>: 2023-03-28</p><p><b>addresses</b>: <a href=\"Condition-PatientKimMusterperson-PrimaryDiagnosis-2.html\">Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet</a></p><p><b>supportingInfo</b>: <a href=\"ClinicalImpression-mii-exa-mtb-kim-musterperson-behandlungsepisode.html\">ClinicalImpression: status = completed; effective[x] = 2023-01-20 --&gt; 2023-03-28</a></p><blockquote><p><b>activity</b></p><p><b>outcomeReference</b>: <a href=\"Procedure-MTBChemo2Procedure.html\">Procedure Chemotherapy</a></p><p><b>reference</b>: <a href=\"MedicationRequest-mii-exa-mtb-medication-request-mirvetuximab.html\">MedicationRequest: extension = 1,m1A,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"ServiceRequest-mii-exa-mtb-study-request-cldn6.html\">ServiceRequest Referral to clinical trial (procedure)</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"ServiceRequest-mii-exa-mtb-study-request-tedova.html\">ServiceRequest Referral to clinical trial (procedure)</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"ServiceRequest-mii-exa-mtb-study-request-ccne1.html\">ServiceRequest Referral to clinical trial (procedure)</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"MedicationRequest-mii-exa-mtb-medication-request-trastuzumab-deruxtecan.html\">MedicationRequest: extension = 3,m1B,http://www.ncbi.nlm.nih.gov/pubmed#35665782,http://www.ncbi.nlm.nih.gov/pubmed#37870536,http://doi.org#10.1200/JCO.2023.41.17_suppl.LBA3000; status = draft; intent = proposal; medication[x] = Trastuzumab deruxtecan; authoredOn = 2023-03-28</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"RequestGroup-mii-exa-mtb-request-group-adavosertib-carboplatin.html\">RequestGroup Chemotherapie + zielgerichtete Substanzen</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"RequestGroup-mii-exa-mtb-request-group-lunresertib-camonsertib.html\">RequestGroup zielgerichtete Substanzen</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"MedicationRequest-mii-exa-mtb-medication-request-cobimetinib.html\">MedicationRequest: extension = 6,m3,http://www.ncbi.nlm.nih.gov/pubmed#31209687; status = draft; intent = option; medication[x] = COBIMETINIB; authoredOn = 2023-03-28</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"ServiceRequest-mii-exa-mtb-kim-humangenetische-beratung-aszites.html\">ServiceRequest Genetic consultation (procedure)</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"ServiceRequest-mii-exa-mtb-kim-histologie-evaluation-aszites.html\">ServiceRequest Refer for histology (procedure)</a></p></blockquote><blockquote><p><b>activity</b></p><p><b>reference</b>: <a href=\"ServiceRequest-mii-exa-mtb-kim-rebiopsie-aszites.html\">ServiceRequest Biopsy (procedure)</a></p></blockquote></div>"
  },
  "status" : "active",
  "intent" : "plan",
  "category" : [
    {
      "coding" : [
        {
          "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ",
          "code" : "praeth"
        }
      ]
    }
  ],
  "subject" : {
    🔗 "reference" : "Patient/PatientKimMusterperson"
  },
  "created" : "2023-03-28",
  "addresses" : [
    {
      🔗 "reference" : "Condition/PatientKimMusterperson-PrimaryDiagnosis-2"
    }
  ],
  "supportingInfo" : [
    {
      🔗 "reference" : "ClinicalImpression/mii-exa-mtb-kim-musterperson-behandlungsepisode"
    }
  ],
  "activity" : [
    {
      "outcomeReference" : [
        {
          🔗 "reference" : "Procedure/MTBChemo2Procedure"
        }
      ],
      "reference" : {
        🔗 "reference" : "MedicationRequest/mii-exa-mtb-medication-request-mirvetuximab"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "ServiceRequest/mii-exa-mtb-study-request-cldn6"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "ServiceRequest/mii-exa-mtb-study-request-tedova"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "ServiceRequest/mii-exa-mtb-study-request-ccne1"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "MedicationRequest/mii-exa-mtb-medication-request-trastuzumab-deruxtecan"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "RequestGroup/mii-exa-mtb-request-group-adavosertib-carboplatin"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "RequestGroup/mii-exa-mtb-request-group-lunresertib-camonsertib"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "MedicationRequest/mii-exa-mtb-medication-request-cobimetinib"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "ServiceRequest/mii-exa-mtb-kim-humangenetische-beratung-aszites"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "ServiceRequest/mii-exa-mtb-kim-histologie-evaluation-aszites"
      }
    },
    {
      "reference" : {
        🔗 "reference" : "ServiceRequest/mii-exa-mtb-kim-rebiopsie-aszites"
      }
    }
  ]
}